An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy

Table 2 Multivariate Cox regression analysis of overall survival in each dataset

	Multivariate analysis
	HR	95% CI	p value
Training cohort
GSE31312 (n = 449)
Age	1.03	1.01–1.04	1.38 × 10⁻⁵
Extra nodal sites number	1.20	1.03–1.41	2.37 × 10⁻²
Stage	1.31	1.12–1.52	6.26 × 10⁻⁵
ECOG^a	1.41	1.21–1.64	7.33 × 10⁻⁶
Resistance probability of doxorubicin	2.70	1.24–5.86	1.23 × 10⁻²
Resistance probability of vincristine	1.28	0.61–2.70	0.51
Validating cohort
GSE10846 (n = 342)
Age	1.02	1.01–1.04	1.45 × 10⁻⁴
Extra nodal sites number	0.99	0.80–1.22	0.95
Stage	1.41	1.19–1.67	5.40 × 10⁻⁵
ECOG^a	1.59	1.32–1.91	6.43 × 10⁻⁷
Resistance probability of doxorubicin	3.24	1.41–7.45	5.61 × 10⁻³
Resistance probability of vincristine	1.40	0.61–3.23	0.43

HR hazard ratio, 95% CI 95% confidence interval
^aThe Eastern Cooperative Oncology Group (ECOG) performance score ranges from 0 to 3, with a higher score indicating greater impairment